CN103403550B - 使用与braf v600e特异性结合的抗体诊断癌症的工具和方法 - Google Patents

使用与braf v600e特异性结合的抗体诊断癌症的工具和方法 Download PDF

Info

Publication number
CN103403550B
CN103403550B CN201180056079.4A CN201180056079A CN103403550B CN 103403550 B CN103403550 B CN 103403550B CN 201180056079 A CN201180056079 A CN 201180056079A CN 103403550 B CN103403550 B CN 103403550B
Authority
CN
China
Prior art keywords
antibody
braf
cancer
sample
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180056079.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103403550A (zh
Inventor
H.岑特格拉夫
A.冯戴姆林
D.卡佩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Universitaet Heidelberg
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Universitaet Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ, Universitaet Heidelberg filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of CN103403550A publication Critical patent/CN103403550A/zh
Application granted granted Critical
Publication of CN103403550B publication Critical patent/CN103403550B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201180056079.4A 2010-09-30 2011-09-30 使用与braf v600e特异性结合的抗体诊断癌症的工具和方法 Active CN103403550B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38815810P 2010-09-30 2010-09-30
US61/388158 2010-09-30
US201161503950P 2011-07-01 2011-07-01
US61/503950 2011-07-01
PCT/EP2011/067092 WO2012042009A1 (en) 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e

Publications (2)

Publication Number Publication Date
CN103403550A CN103403550A (zh) 2013-11-20
CN103403550B true CN103403550B (zh) 2015-08-19

Family

ID=44789447

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180056079.4A Active CN103403550B (zh) 2010-09-30 2011-09-30 使用与braf v600e特异性结合的抗体诊断癌症的工具和方法

Country Status (9)

Country Link
US (1) US9297812B2 (enExample)
EP (1) EP2622348B1 (enExample)
JP (1) JP5893037B2 (enExample)
CN (1) CN103403550B (enExample)
AU (1) AU2011310096B2 (enExample)
CA (1) CA2813098C (enExample)
DK (1) DK2622348T3 (enExample)
ES (1) ES2554678T3 (enExample)
WO (1) WO2012042009A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172744B (zh) * 2012-09-28 2016-01-13 武汉纽斯特生物技术有限公司 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
JP6485854B2 (ja) * 2014-09-24 2019-03-20 国立研究開発法人国立循環器病研究センター 抗変異型プロテインｓ抗体、該抗体を含む診断用組成物、変異型ヒトプロテインｓの検出方法および該抗体を含むキット
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
JP6941688B2 (ja) 2017-06-29 2021-09-29 コリア アドヴァンスド インスティテュート オブ サイエンス アンド テクノロジー 神経節膠腫が誘導された動物モデルならびに神経節膠腫およびこれに関連する疾患の診断用組成物
CN110183535A (zh) * 2018-12-17 2019-08-30 南京基诺米医疗科技有限公司 鼠抗人braf v600e突变蛋白单克隆抗体制备及其免疫组化用途
CN111285935B (zh) * 2020-05-13 2020-09-11 方达医药技术(上海)有限公司 特异性检测braf基因突变的抗体及其在制备癌症检测试剂盒中的用途
WO2022104200A1 (en) * 2020-11-16 2022-05-19 Agilent Technologies, Inc. Chimeric anti-human braf v600e antibodies and methods for making and using them
WO2024090265A1 (ja) * 2022-10-28 2024-05-02 株式会社biomy 情報処理装置、情報処理方法及びプログラム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047542A1 (en) * 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
WO2007002811A2 (en) * 2005-06-29 2007-01-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6735531B2 (en) * 1996-10-07 2004-05-11 Lab Vision Corporation Method and apparatus for automatic tissue staining
JP2009077712A (ja) 2007-09-11 2009-04-16 F Hoffmann La Roche Ag Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験
KR20100065189A (ko) 2007-09-11 2010-06-15 유니버시티 오브 매사추세츠 암을 치료하기 위한 인슐린­유사 성장 인자 결합 단백질 7

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047542A1 (en) * 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
WO2007002811A2 (en) * 2005-06-29 2007-01-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma

Also Published As

Publication number Publication date
EP2622348B1 (en) 2015-09-16
US20130266962A1 (en) 2013-10-10
ES2554678T3 (es) 2015-12-22
AU2011310096B2 (en) 2014-11-06
DK2622348T3 (en) 2015-12-14
JP5893037B2 (ja) 2016-03-23
AU2011310096A1 (en) 2013-04-18
WO2012042009A1 (en) 2012-04-05
CA2813098C (en) 2019-10-08
CA2813098A1 (en) 2012-04-05
US9297812B2 (en) 2016-03-29
EP2622348A1 (en) 2013-08-07
JP2013543117A (ja) 2013-11-28
CN103403550A (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
CN103403550B (zh) 使用与braf v600e特异性结合的抗体诊断癌症的工具和方法
JP6075881B2 (ja) 乳癌のバイオマーカー
JP5767116B2 (ja) 白金に基づく治療に対する応答の予測
CN102803968B (zh) 食道癌标志物
EP2318841B1 (en) Anln protein as an endocrine treatment predictive factor
US20190154694A1 (en) Detection and treatment of cancer
US20110003854A1 (en) Breast cancer treatment and treatment prediction
EP2288721B1 (en) Treatment prediction involving hmgcr protein
EP2243032B1 (en) Rbm3 as a marker for breast cancer prognosis
CN102089442B (zh) 涉及hmgcr蛋白的治疗预测
EP2293070A1 (en) Means and methods for ovarian cancer prognosis
CN117929748A (zh) Icam-1蛋白在制备非小细胞肺癌免疫治疗预测试剂盒中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant